Latest Conference Articles

Survey: US Pharmacists Have Homework to Do on Biosimilar Interchangeability

Tony Hagen

October 23 2021

Pharmacists need to brush up on their knowledge of the interchangeable biosimilar designation, investigators said in a survey presentation at the Academy of Managed Care Pharmacy Nexus 2021 meeting.

Amgen Executive Discusses Prominent Biosimilar Trends

October 21 2021

In this interview with The Center for Biosimilars®, Amgen biosimilars expert Jen Norton discusses regulatory and policy incentives, interchangeable biosimilars, and market share gains.

Coherus BioSciences Reaches Clinical and Regulatory Milestones for Udenyca and CHS-201

Tony Hagen

October 6 2021

Positive findings for Coherus BioSciences' ranibizumab candidate (CHS-201) were presented at the Scientific Meeting of the Retina Society, and the company said equivalence end points were met for an on-body injector version of Udenyca (pegfilgrastim).

Remsima Delivers Positive Results in IBD Switching Study

Tony Hagen

October 4 2021

Studies of the infliximab biosimilar Remsima in patients with inflammatory bowel disease were presented at United European Gastroenterology Week 2021.

Tanvex Presents Positive Findings for Trastuzumab Candidate at ESMO

Tony Hagen

September 20 2021

Investigators said TX05 met pathologic complete response criteria for equivalence to the originator product, Herceptin. The biosimilar candidate also fell within objective response rate, immunogenicity, safety, and tolerability margins for similarity.

Biocad's BCD-021 Bevacizumab Biosimilar Demonstrates Equivalence in NSCLC

Tony Hagen

September 17 2021

BCD-021 demonstrated equivalence in a phase 3 study involving Russian and Indian patients with advanced non–small cell lung cancer (NSCLC).

MIL60 Bevacizumab Biosimilar Candidate Demonstrates Equivalence in NSCLC

Tony Hagen

September 16 2021

MIL60 bevacizumab biosimilar candidate demonstrates equivalence to the originator Avastin in a population of Chinese patients with non–small cell lung cancer (NSCLC) treated in a frontline setting.

Samsung Bioepis Reports Long-term Ontruzant Findings for HER2-Positive Breast Cancer

Tony Hagen

September 14 2021

The positive findings for the trastuzumab biosimilar Ontruzant in patients with human epidermal growth factor receptor 2 (HER2)–positive early or locally advanced breast cancer were presented at the European Society for Medical Oncology (ESMO) Congress 2021.

Investigators Elucidate ADA Predictive Value of Infliximab Clearance in Crohn Disease

Tony Hagen

July 26 2021

Concomitant use of immunomodulators and dosage are important variables in the development of antidrug antibodies (ADAs) for patients receiving infliximab for Crohn disease, investigators report.

Investigators Report Findings on Infliximab Switching in IBD

Tony Hagen

July 21 2021

Pharmacokinetic, safety, and efficacy findings for patients with inflammatory bowel disease (IBD) were presented at the European Crohn's and Colitis Organization's annual meeting.